Lilly Biotechnology Center
BIOGRAPHY
Speaker
Event Date & Time
Date: November 16, 2022
Time: 10:00am (PST), 1:00pm (EST), 7:00pm (CET)
Abstract
Eli Lilly, a global healthcare leader, has implemented a next generation research (NGR) initiative to improve the value output of the R&D portfolio. One of the NGR pillars focuses on decreasing the timeline to bring medicines to patients. Lilly has invested in ‘Islands of Automation’ to advance the B cell antibody discovery platform at the Lilly Biotechnology Center in San Diego with the goal of significantly increasing throughput and reducing project timelines.
In this webinar, Paul Anderson, Director - Biologics Discovery Automation at Eli Lilly will focus on the automated systems that have been developed as part of this platform. This highly automated approach to antibody discovery has enabled Lilly to meet aggressive timelines and dramatically increase throughput while allowing flexibility for future changes to its process.
Learning Objectives
- Monoclonal antibody discovery from single B cells
- Modular automated systems that allow for maximum flexibility to support several workflows in addition to monoclonal antibody discovery
- Automated system design and optimization
Webinars will be available for unlimited on-demand viewing after live event.
You May Also Like
DEC 10, 2024 | 9:00 AM
To-date, proteomic analysis has been severely limited in scale and resolution. Analyzing protein samples using an intact, single-molecule approach holds th...
OCT 02, 2024 | 7:30 AM
De novo gene synthesis and protein expression are established technologies that can give access to nearly any target DNA or protein sequence, allowing for engineering of biologics. In this p...
Loading Comments...